ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patientsTeodoro Vargas, Ana Ramı́rez de Molina, Juan Moreno‐Rubio et al.|Oncotarget|2015Cited by 76
Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, Ricardo Yayá et al.|Molecular Cancer Therapeutics|2014Cited by 12
Pharmacogenetic profiling for oxaliplatin-based adjuvant chemotherapy (CT) benefit in stage II-III colon cancer (CC) patients: A GEMCAD study.Jaime Feliú, Paloma Cejas, Ana Custodio et al.|Journal of Clinical Oncology|2012Cited by 0
Pharmacogenetic predictors of adverse events in stage II-III colon cancer (CC) patients treated with oxaliplatin and fluoropyrimidines-based adjuvant chemotherapy (CT): A GEMCAD study.Ana Custodio, Juan Antonio Moreno, Jorge Aparicio et al.|Journal of Clinical Oncology|2012Cited by 0
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, Juan Moreno‐Rubio et al.|Unknown|2023Cited by 0